FOUNTAIN HILLS, Ariz., Feb. 23, 2011 /PRNewswire/ -- Sunridge International (OTC Bulletin Board/OTCQB: SNDZ), announced today the signing of an exclusive distribution contract for Turkey. Based on Turkey's population of approximately 75 million people, the 5-year contract with New Amsterdam Marketing Corporation, should provide a substantial increase in sales. Preparations are currently being made for Sunridge to send medical personnel to train local key opinion leaders to assist New Amsterdam's marketing rollout.
Sunridge's CEO, G. Richard Smith stated, "Our goal has always been to expand our distribution network. With the signing of this agreement, along with the distribution rights to several additional countries throughout Europe that we are currently negotiating, we are very pleased with the progress that we are making."
"Recently we expanded our business model to include the addition of company owned clinics, which is a more aggressive approach for Sunridge. Our funding efforts for the clinics is progressing well at this time, and we look forward to advancing into this highly profitable market."
Glaucoma is the second leading cause of blindness, affecting over 70 million people worldwide. PNT has been proven (through studies completed over the last 10 yrs) to be a safe, effective, non-invasive and a cost effective alternative for treatment for glaucoma and ocular hypertension. The 2-minute treatment has been developed, patented, and distributed by Sunridge International, wholly owned subsidiary, Ophthalmic International www.oi-pnt.com.
SOURCE Sunridge International